A microRNA profile comparison in patients with different venous insufficiency grades.

• Grant number: 18/06422-8
• Support Opportunities: Regular Research Grants
• Start date: May 01, 2019
• End date: April 30, 2022
• Field of knowledge: Health Sciences - Medicine - Surgery
• Principal Investigator: Winston Bonetti Yoshida
• Grantee: Winston Bonetti Yoshida
• Host Institution: Faculdade de Medicina (FMB). Universidade Estadual Paulista (UNESP). Campus de Botucatu. Botucatu , SP, Brazil
• Associated researchers: Matheus Bertanha ; Patricia Pintor dos Reis
• Associated scholarship(s): 20/02702-6 - A microRNA profile comparison in patients with different venous insufficiency grades, BP.TT

Abstract

The occurrence of primary varicose veins may be associated with age, obesity, number of pregnancies and standing posture. Varicose veins are more prevalent also in patients with a family history of varicose veins, which has led to a number of investigations into genetic mechanisms in their genesis and changes in the expression of proteins in patients with varicose veins. Only two studies evaluated the influence of the expression of gene expression regulatory molecules as microRNAs (miRNAs) on the pathophysiology of the same disease. However, these studies only looked at patients with moderate varicose veins (Clinical-Etiology-Anatomy-Pathophysiology, CEAP = 4). Therefore, there is still a need to broaden the spectrum of evaluation of this pathology, including patients with varicose veins of different degrees of disease severity. Thus, we propose to determine and compare the overall expression profile of miRNAs in varicose vein samples from patients with chronic venous insufficiency and varicose veins from CEAP 2 to CEAP 5. Five patients will be selected per group: Group 1- Reference without varices (CEAP 0 ); Group 2 - CEAP 2; Group 3 - CEAP 3; Group 4 - CEAP 4 and Group 5 CEAP 5. The groups with primary varicose veins will have clinical diagnosis and duplex mapping and will undergo conventional varicose vein surgery. From these patients, varicose vein saphenous vein samples will be obtained and used for analysis of miRNA expression. The overall expression of miRNAs will be determined using the GeneChip microRNA array platform (Thermo Fisher Scientific). The miRNAs with abnormal expression will be mapped into molecular pathways potentially associated with the development and progression of the disease. Studies such as these may have important future implications on prognosis and in identifying new treatment strategies for patients (AU)